Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease whose causes are still poorly understood. To identify additional genetic risk factors, we assessed the role of de novo mutations in ALS by sequencing the exomes of 47 ALS patients and both of their unaffected parents (n = 141 exomes). We found that amino acid-altering de novo mutations were enriched in genes encoding chromatin regulators, including the neuronal chromatin remodeling complex (nBAF) component SS18L1 (also known as CREST). CREST mutations inhibited activity-dependent neurite outgrowth in primary neurons, and CREST associated with the ALS protein FUS. These findings expand our understanding of the ALS genetic landscape and provide a resource for future studies into the pathogenic mechanisms contributing to sporadic ALS. 
a r t I C l e S ALS, also known as Lou Gehrig's disease, is a fatal adult-onset neurodegenerative disease characterized by loss of motor neurons 1 . Although ~10% of cases have a family history of ALS (FALS), the majority of cases are sporadic (SALS). There have been several recent advances in defining the genetic landscape of FALS. These include the discovery that mutations in TARDBP, FUS, VCP, OPTN, UBQLN2, C9orf72 and PFN1 are causes of FALS [2] [3] [4] [5] [6] [7] [8] [9] [10] . Together with mutations in SOD1 (ref. 11) , the causes of two thirds of FALS cases have now been elucidated. There have also been substantial inroads into understanding SALS etiology, and genetic contributors for ~11% of SALS cases have been discovered. As it is likely that genetics is central for this form of the disease, there is intense interest in defining additional genetic causes and risk factors for SALS.
A possible genetic mechanism for sporadic disease is de novo mutation, in which a mutation arises spontaneously in the germline of one of the unaffected parents. Indeed, de novo mutations have recently been identified as contributors to neurodevelopmental disorders such as autism spectrum disorders, schizophrenia and mental retardation [12] [13] [14] [15] [16] [17] [18] . There have been confirmed de novo mutations in known ALS genes in apparently SALS cases [19] [20] [21] , indicating that, in principle, this mechanism could also contribute to ALS.
RESULTS
To test the hypothesis that de novo mutations contribute to risk for ALS, we performed a systematic analysis of ALS trios (ALS patient and both unaffected parents; Fig. 1a) . Because ALS is a late-onset disease, trios for which DNA samples are available for patients and their parents are much rarer than for early-onset ones, such as autism. Nevertheless, we were able to assemble a collection of 47 ALS trios and we performed whole-exome sequencing on all 141 individuals (47 × 3 = 141 exomes). We pre-screened all 47 ALS cases for the C9orf72 hexanucleotide repeat expansion 9,10 and they were all negative (Supplementary Table 1) .
We achieved an average coverage of 56× across all samples, and an average of 87% of the target bases in each individual were covered by at least ten independent sequence reads (Supplementary Table 2 ). After validation by Sanger sequencing, we identified 25 previously unknown de novo amino acid-altering variants (non-synonymous): 20 missense, 1 nonsense, 1 splicing, 2 frameshift and 1 in-frame deletion ( Table 1 ). The observed de novo mutation rate is consistent with those reported in recent studies of autism spectrum disorders [12] [13] [14] [15] (Supplementary Table 3 ). The frequency distribution of de novo non-synonymous mutations closely followed a Poisson distribution, indicating that multiple de novo events in a single individual do not contribute to ALS risk (Supplementary Fig. 1 ).
We first asked whether there are any functional categories or cellular pathways enriched in this list. Functional annotation analysis performed with DAVID (v6.7) 22 revealed a significant enrichment of genes encoding chromatin regulators (5 of 25: EHMT1, FOXA1, HDAC10, SRCAP and SS18L1 (B.T.S., J. Tang, W. Wu, a r t I C l e S A. Sun, A.D.G., A. Yoo and G.R.C., unpublished observations), P = 0.01, corrected for the multiple pathways that were tested). Are de novo mutations simply more common in chromatin regulator genes or is this enrichment in our ALS list meaningful? To address this question, we sought a control set of trios. The recent analysis of de novo mutations in autism spectrum disorders included some exome data on unaffected siblings 12 . We used the de novo mutations found in unaffected siblings (n = 50) to perform the same functional analysis. This list of de novo mutations was not enriched for any functional category (Supplementary Fig. 2 ), supporting the idea that chromatin regulator genes and defects in chromatin regulation could contribute to ALS. Indeed, drugs modulating histone acetylation have been shown to have protective effects in ALS mouse models and induced pluripotent stem cell-derived motor neurons from ALS patients [23] [24] [25] and have undergone phase 2 clinical studies in ALS subjects 26 . Our results suggest that there are also potential genetic connections to ALS.
Three genes on the list have been implicated in neurite outgrowth (NTM, VCL and SS18L1) [27] [28] [29] [30] [31] . Defects in neurite outgrowth have been seen in zebrafish models of ALS 32 and in induced pluripotent stem cell-derived motor neurons from ALS patients 25 . One of these genes, SS18L1 (also known as CREST), is expressed only in post-mitotic neurons and encodes an essential subunit of a neuron-specific chromatinremodeling complex (nBAF, also known as mSWI/SNF; B.T.S., J. Tang, W. Wu, A. Sun, A.D.G., A. Yoo and G.R.C., unpublished observations) that resembles yeast SWI/SNF and SWR 33 . nBAF controls activity-induced dendrite outgrowth 29, 31 and is strongly expressed in the brain and spinal cord, where it localizes to the nucleus (Fig. 1) .
CREST is a calcium-regulated transcriptional activator, a property that requires the last nine amino acids of CREST, which is reported to interact with the histone acetylase CBP (Fig. 1b,c and ref. 29) . Notably, we identified a de novo mutation in CREST that introduces a stop codon removing the exact same nine amino acids (Q388stop; Table 1 and Fig. 1b) .
To determine the functional relevance of this mutation in neurons, we tested its effects in primary cortical neurons isolated from mouse embryos. Depolarizing these primary neuronal cultures with KCl induced marked dendrite outgrowth (Fig. 1d) , increasing the total dendrite length (Fig. 1e) and number of dendritic branch points per neuron (Fig. 1f) . We transfected these neurons with GFP, wild-type CREST or a mutant CREST lacking the last 9 amino acids (CREST , this truncation in the mouse CREST homolog corresponds to CREST in human CREST; Fig. 1b) . Expression of GFP or wild-type CREST had no effect on KCl-induced dendrite outgrowth ( Fig. 1d-f) , whereas the presence of mutant CREST inhibited dendrite outgrowth (Fig. 1d,e ) and decreased complexity of the dendritic arbors (Fig. 1f) . These functional studies in primary neurons indicate that this mutation is likely deleterious and its dominant-negative properties are consistent with a heterozygous mutation being able to cause disease.
To further explore whether SS18L1 has a role in ALS, we analyzed exome sequence data from index cases of 62 families with a history of ALS and that did not contain mutations in any of the genes known to be involved in ALS, including C9orf72. In one case (individual III:2, family ALS296; Fig. 2a ), we identified a missense mutation (I123M) that was absent from public single nucleotide polymorphism (SNP) a r t I C l e S and exome databases. We also performed targeted SNP genotyping on 693 control individuals from the same population and found that this variant was absent. Re-sequencing in this family revealed that the I123M variant was absent from the unaffected parent of this index case, implying segregation of the mutation from the affected (deceased) parent (Fig. 2a) . To test the functional relevance of this variant and to extend our studies to a cell type more clinically relevant to ALS, we tested its effects in cultures of primary motor neurons isolated from mouse embryos. We transfected motor neurons with GFP, wild-type CREST or the two mutants (CREST or CREST I123M ). Compared with GFP or wild-type CREST, expression of CREST or CREST I123M substantially blocked depolarization-induced dendrite outgrowth (Fig. 2b) and the increase in dendritic arbor complexity (Fig. 2c) . Thus, these results in primary motor neurons support the pathogenicity of the two CREST variants identified in ALS patients. The defects in dendritic morphology elicited by the two CREST mutant proteins in our primary neuron experiments are reminiscent of dendrite patterning defects observed in neurons cultured from FUSdeficient mice 34 . We therefore considered the possibility that FUS and CREST might physically associate. We conducted mass spectrometry studies of nBAF complexes that were affinity purified at low stringency (150 mM NaCl, 0.1% NP-40, 50 mM Tris-HCL, pH 8.0) from postnatal day 1 (P1) cortical neurons for proteins that interact with nBAF. We detected 81 peptides from FUS, representing 29.6% coverage in these mass spectrometry studies. To further explore the potential physical interaction of FUS and CREST, we performed immunoprecipitation assays using nuclear extracts isolated from P1 mouse cortical neurons. Immunoprecipitating endogenous CREST from these extracts, followed by immunoblotting with an antibody to FUS, revealed that CREST and FUS interacted in neurons (Fig. 2d) . We noted the interaction between CREST and FUS when using the reciprocal immunoprecipitation (FUS antibody for immunoprecipitation, CREST antibody for immunoblot) was nearly undetectable. This could be indicative of different relative abundances. FUS might be more abundant than CREST, leading us to detect the interaction only from one direction. Another possibility is that the FUS antibody masks the binding site of CREST on FUS. To address this, we performed quantitative western blots to determine the amounts of FUS and Brg (the core ATPase used as a representative of the nBAF complexes of which CREST is a core subunit) per cell. We estimated there to be 3 × 10 5 molecules of BRG and 1.2 × 10 6 molecules of FUS per cell (data not shown). Thus, FUS is not a core BAF complex component and only transiently associates with CREST, perhaps in a regulatory role.
Because CREST is a dedicated subunit of the nBAF complex in neurons, we tested whether using antibodies to other nBAF subunits would immunoprecipitate FUS. Indeed, we found that many of the BAF subunits weakly co-immunoprecipitated FUS (Fig. 2e) . As the nBAF-FUS interaction was most detectable with antibodies to CREST, FUS might bind to a surface on nBAF complexes other than CREST. This surface might be on Brg or BAF57, as the co-immunoprecipitation of FUS was undetected by western blot, indicating that the antibodies to these subunits could be blocking the nBAF-FUS interaction. Alternatively, the CREST antibody might induce allosteric changes in CREST that expose a FUS-interacting domain, which would explain why the CREST co-immunoprecipitation of FUS was the strongest of any subunit. Together, these results suggest that CREST and the nBAF chromatin remodeling complex can associate with FUS in neurons.
Bioinformatics analysis revealed the presence of predicted prionlike domains in CREST and SS18 (Supplementary Fig. 3 ). These domains are present in an expanding class of proteins associated with neurodegenerative disease, including TDP-43, FUS, TAF15, EWSR1, hnRNPA2B1 and hnRNPA1, and are able to drive aggregation of these proteins [35] [36] [37] [38] [39] [40] . In the future, it will be important to define how CREST's prion-like domain contributes to its normal function and if it npg a r t I C l e S facilitates co-aggregation with FUS or other aggregation-prone RNAbinding proteins in disease. Together, these data support a potential role of the identified CREST variants in ALS and implicate additional nBAF complex components as candidates for further investigation in the disease.
DISCUSSION
We sequenced the exomes of 47 ALS trios. These results provide a systematic analysis of de novo mutations in ALS and we identified genes encoding chromatin regulators as new candidates for ALS genetic contributors. Notably, in addition to CREST, we identified a de novo truncating mutation in SRCAP in another ALS trio ( Table 1) . Similar to CREST, SRCAP is also a CBP-interacting transcriptional co-activator 41 , further underscoring a potential role of CBPassociated chromatin regulators in ALS. Indeed, FUS itself is a key transcriptional regulator via interactions with CBP 42 . Mutations in 8 of 15 subunits of BAF complexes have been identified as causative in Coffin-Siris, a rare congenital anomaly syndrome characterized by growth deficiency, intellectual disability, microcephaly, coarse facial features, and hypoplastic nail of the fifth finger and/or toe 43, 44 , and Nicolaides-Baraitser syndromes, which include features of intellectual disability with marked language impairment, microcephaly, epilepsy and morphological defects 45, 46 , and have also been found in sporadic autism 10 , intellectual disability 47 and schizophrenia 48 . It is tempting to speculate about possible pathophysiological connections between neurodevelopmental and neurodegenerative disorders 49 .
Beyond the chromatin regulator genes, the identification of a de novo mutation in the type XIX collagen gene COL19A1 is notable because the expression of this molecule has recently been shown to be markedly upregulated in the muscle at the end stage of disease in a mouse model of inherited ALS (SOD1 G39A ), and Col19a1 expression negatively correlates with survival 50 . Future studies will be required to define the effect of this variant on COL19A1 expression and the effect it has on muscle function during disease progression.
Additional functional studies in cell culture and animal models as well as re-sequencing these genes in larger ALS patient populations will be needed to assess the pathogenicity of the genes that we identified. We propose that the specific genes we found, as well as their network of interacting partners (genetic and physical interactions), especially the other components of the CREST-containing nBAF chromatin remodeling complex, are now candidates for evaluation in larger ALS patient cohorts. Using the autism exome sequencing efforts as a guide [12] [13] [14] [15] , we anticipate that increasing the number of ALS trios analyzed, integrating data from multiple studies and focusing on key nodes in protein interaction networks will help to strengthen and focus disease gene discovery efforts. Finally, this approach could be applied broadly to other neurodegenerative diseases, such as Parkinson disease and Alzheimer disease.
METhODS
Methods and any associated references are available in the online version of the paper. 
